文献速递糖尿病

脐带来源间充质基质细胞保留1型糖尿病内源性胰岛素分泌:一项I/II期随机双盲安慰剂对照试验

Umbilical cord-derived mesenchymal stromal cells preserve endogenous insulin production in type 1 diabetes: a Phase I/II randomised double-blind placebo-controlled trial.
PubMed 文献 · Diabetologia · 2023-05-24

这项在瑞典斯德哥尔摩卡罗林斯卡大学医院开展的I/II期试验,先进行剂量递增,随后将15例新诊断1型糖尿病成人随机分配至异体沃顿胶来源间充质基质细胞(ProTrans)组(10例)或安慰剂组(5例)。1年后安慰剂组混合餐耐量试验C肽AUC较基线下降47%,ProTrans组仅下降10%(p<0.05);安慰剂组胰岛素需求量中位数增加10 U/天,ProTrans组12个月随访期内无变化(p<0.05)。未观察到与治疗相关的严重不良事件。

要点

  • ProTrans组1年C肽AUC较基线下降10%,安慰剂组下降47%(p<0.05)。
  • 安慰剂组胰岛素需求量中位数增加10 U/天,ProTrans组12个月随访期内无变化(p<0.05)。
  • 未观察到与治疗相关的严重不良事件,不良事件总体较少,主要为轻度上呼吸道感染。

核心结论

  • 该研究提示异体沃顿胶来源间充质基质细胞(ProTrans)是近期起病1型糖尿病的安全治疗方法,具有保留β细胞功能的潜力。

研究设计与样本

  • 在瑞典斯德哥尔摩卡罗林斯卡大学医院开展的I/II期试验,由剂量递增部分和随机双盲安慰剂对照平行设计部分组成。
  • 纳入标准为入组前2年内诊断1型糖尿病、年龄18-40岁、空腹血浆C肽浓度>0.12 nmol/l。
  • 剂量递增部分每个剂量队列纳入3例参与者;随机部分纳入15例参与者,其中10例分配至ProTrans治疗、5例分配至安慰剂。
  • 所有参与者均纳入主要和次要结局分析。

主要发现

  • 1年时混合餐耐量试验C肽AUC较基线变化:安慰剂组下降47%,ProTrans组仅下降10%(p<0.05)。
  • 12个月随访期内胰岛素需求量:安慰剂组中位数增加10 U/天,ProTrans组无变化(p<0.05)。
  • 未观察到与治疗相关的严重不良事件,活性治疗组和安慰剂组总体不良事件较少,主要为轻度上呼吸道感染。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM/HYPOTHESIS: This study aimed to investigate the safety and efficacy of treatment with allogeneic Wharton's jelly-derived mesenchymal stromal cells (MSCs) in recent-onset type 1 diabetes. METHODS: A combined Phase I/II trial, composed of a dose escalation followed by a randomised double-blind placebo-controlled study in parallel design, was performed in which treatment with allogeneic MSCs produced as an advanced therapy medicinal product (ProTrans) was compared with placebo in adults with newly diagnosed type 1 diabetes. Inclusion criteria were a diagnosis of type 1 diabetes <2 years before enrolment, age 18-40 years and a fasting plasma C-peptide concentration >0.12 nmol/l. Randomisation was performed with a web-based randomisation system, with a randomisation code created prior to the start of the study. The randomisation was made in blocks, with participants randomised to ProTrans or placebo treatment. Randomisation envelopes were kept at the clinic in a locked room, with study staff opening the envelopes at the baseline visits. All participants and study personnel were blinded to group assignment. The study was conducted at Karolinska University Hospital, Stockholm, Sweden. RESULTS: Three participants were included in each dose cohort during the first part of the study. Fifteen participants were randomised in the second part of the study, with ten participants assigned to ProTrans treatment and five to placebo. All participants were analysed for the primary and secondary outcomes. No serious adverse events related to treatment were observed and, overall, few adverse events (mainly mild upper respiratory tract infections) were reported in the active treatment and placebo arms. The primary efficacy endpoint was defined as Δ-change in C-peptide AUC for a mixed meal tolerance test at 1 year following ProTrans/placebo infusion compared with baseline performance prior to treatment. C-peptide levels in placebo-treated individuals declined by 47%, whereas those in ProTrans-treated individuals declined by only 10% (p<0.05). Similarly, insulin requirements increased in placebo-treated individuals by a median of 10 U/day, whereas insulin needs of ProTrans-treated individuals did not change over the follow-up period of 12 months (p<0.05). CONCLUSIONS/INTERPRETATION: This study suggests that allogeneic Wharton's jelly-derived MSCs (ProTrans) is a safe treatment for recent-onset type 1 diabetes, with the potential to preserve beta cell function. TRIAL REGISTRATION: ClinicalTrials.gov NCT03406585 FUNDING: The sponsor of the clinical trial is NextCell Pharma AB, Stockholm, Sweden.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Carlsson PO, Espes D, Sisay S, et al. Umbilical cord-derived mesenchymal stromal cells preserve endogenous insulin production in type 1 diabetes: a Phase I/II randomised double-blind placebo-controlled trial. Diabetologia. 2023. PMID: 37221247. doi:10.1007/s00125-023-05934-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。